Replies to post #366346 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"There were no sae’s attributed to B! Stop with the bs"

No bullshit.

This seems to be the part of my comment you think is erroneous:

"But as between 80% and 100% of subjects in the daptomycin comparison study experienced Adverse Events while on brilacidin"

I didn't even mention Serious Adverse Events.

Your error probably arises because

1) you are confusing Adverse Events with Serious AEs

and

2) you are confusing "experienced by" with "attributed to" (it helps to know a little bit about pharmacovigilance if one speculates in penny stock biotechs).

But now you mention SAEs, you can see below, between 80% and 100% of subjets receiving brilacidin experienced an adverse event, and there were six Serious Adverse events experienced by patients treated with brilacidin (and none experienced by daptomycin treated subjects):



It's certainly true to say that IPIX' paid investigators say that none of the SAEs experienced by the brilacidin subjects were caused by brilacidin, but to a trained observer the excess of SAEs in the brilacidin arms of both the daptomycin and Oral Mucositis studies is striking, to say the least.